Cabometyx 20 MG tablet 30S
Ended Awarded
- Contract number
- SPE2DR26FMDS7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,949
Award facts
- Contract value 100% obligated
- $33,949.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $33.9K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cabometyx 20 mg tablets (30-count units). This delivery order, issued on October 20, 2025, with completion targeted for October 21, 2025, utilizes firm fixed-price pricing with no set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group is performing under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion DLA acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's underlying Indefinite Delivery Contract with the Defense Logistics Agency, designated SPE2DR and awarded November 13, 2025, carries a $500M ceiling and extends through December 31, 2036, comprising a 30-month base period with three 30-month option periods. The PPV-G GEN V contract authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare operations globally. This specific delivery order for Cabometyx, an oncology treatment, exemplifies DMS Pharmaceutical Group's role as a critical supplier within the federal pharmaceutical supply chain, supporting recurring medical supply needs across the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FMDS7?
SPE2DR26FMDS7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 20, 2025.
How much is contract SPE2DR26FMDS7 worth?
The government has obligated $33,949 on SPE2DR26FMDS7.
Is contract SPE2DR26FMDS7 an order under another contract?
Yes. SPE2DR26FMDS7 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDS7 competed?
The extent of competition for SPE2DR26FMDS7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award